Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects

Published:2016-06-17 Issue:12 Volume:56 Page:1528-1537
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Krishna Rajesh¹,Addy Carol²,Tatosian Daniel¹,Glasgow Xiaoli S.¹,Gendrano III Isaias Noel¹,Robberechts Martine¹,Haazen Wouter³,Hoon J.N.⁴,Depré Marleen⁴,Martucci Ashley¹,Peng Joanna Z.⁵,Johnson‐Levonas Amy O.¹,Wagner John A.⁶,Stoch S. Aubrey¹

Affiliation:

1. Merck & Co Kenilworth NJ USA

2. HMR Weight Management Services Boston MA USA

3. Johnson & Johnson Belgium

4. U.Z. Gasthuisberg Center for Clinical Pharmacology Leuven Belgium

5. Seattle Genetics Bothell WA USA

6. Takeda Pharmaceuticals Cambridge MS USA

Funder

Merck & Co

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.773

Reference16 articles.

1. IDF Diabetes Atlas 6th ed. Brussels Belgium: International Diabetes Federation; 2013.http://www.idf.org/sites/default/files/Atlas‐poster‐2014_EN.pdf.

2. A Systematic Review of Adherence With Medications for Diabetes

3. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among texas medicaid recipients

4. Impact of Dosage Frequency on Patient Compliance

5. Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM);European Journal of Medicinal Chemistry;2024-06

2. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Endocrinology and Metabolism;2024-02-29

3. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis;Endocrinology and Metabolism;2024-02-29

4. Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants;Journal of Medicinal Chemistry;2023-08-30

5. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study);Diabetes Therapy;2023-07-19